PRedicting OutcomeS in Preterm nEonates With thromboCyTopenia

NCT ID: NCT06043050

Last Updated: 2025-09-09

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 1042 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2022-09-26
• Study Completion Date: 2024-04-30

Brief Summary

Preterm neonates often receive platelet transfusions when their platelet count is low to prevent bleeding. However, it is currently unclear which infants benefit from such transfusions. A recent randomized controlled trial (PlaNeT-2/MATISSE trial) showed that the higher platelet count threshold for transfusion was associated with a higher risk of major bleeding or death. Current transfusion protocols are based only on platelet count thresholds. However, neonates with similar platelet counts may have different bleeding risks due to varying clinical conditions. There is an important unmet medical need to identify which neonates with low platelet counts (i.e., severe thrombocytopenia) will benefit from a transfusion. Ideally, clinicians would be able to repeatedly predict a neonate's risk of major bleeding or death with and without giving a platelet transfusion, taking into account the neonate's clinical condition at that particular time. Obtaining personalized risk estimates under specific treatment strategies, with updated predictions at each new treatment decision moment, is called 'sequential prediction under interventions'. The investigators set up an international multicenter observational cohort study to develop a model to predict major bleeding or death with and without platelet transfusion at any time point during the first week after the onset of severe thrombocytopenia. This model is designed to support platelet transfusion decisions in the NICU and may help clinicians balance the benefits and harms of platelet transfusion based on updated characteristics of the neonate at the time of prediction.

Detailed Description

Main objective: To develop a sequential interventional prediction model to support transfusion decisions by predicting the risk of major bleeding or death with and without giving a platelet transfusion to neonates with severe thrombocytopenia (i.e., platelet count below 50x10^9/L), conditional on their characteristics present at the moment of prediction.

Study design: Multicenter international observational cohort study.

Study population: Neonates with a gestational age below 34 weeks and at least one platelet count below 50x10^9/L, admitted to a neonatal intensive care unit (NICU) between January 1st 2017 and January 1st 2022.

Main study endpoint: Major bleeding or mortality during NICU admission

Assessments: Only routine care data will be collected. This includes platelet counts and transfusions, cranial (head) ultrasounds and other information on bleeding, and multiple clinical variables.

Statistical analyses: Development of a sequential prediction model under interventions using the cloning-censoring-weighting approach with inverse probability weighting. Validation of the model in a separate cohort of preterm neonates with severe thrombocytopenia.

Conditions

Neonatal Thrombocytopenia; Intraventricular Hemorrhage; Platelet Transfusion

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: RETROSPECTIVE

Study Groups

Neonates with severe thrombocytopenia

Neonates with a gestational age below 34 weeks and at least one platelet count below 50x10\^9/L, who were admitted to a NICU between January 1st, 2017 and January 1st, 2022.

Platelets

Intervention Type: DRUG

Observational data: all platelet transfusions recorded in routine care medical file data.

Interventions

Platelets

Observational data: all platelet transfusions recorded in routine care medical file data.

Intervention Type: DRUG

Other Intervention Names

Platelet transfusion

Eligibility Criteria

Inclusion Criteria

1. Gestational age at birth <34 weeks;

2. At least one platelet count <50x109/L;

3. Admission to a participating tertiary care NICU, including postnatal transfers, between January 1st, 2017 and January 1st, 2022.

Exclusion Criteria

1. A severe congenital malformation;

2. Only spurious platelet counts <50x109/L (e.g. clots in the sample, or a very rapid recovery to a normal platelet count without platelet transfusion);

3. Only platelet counts <50x109/L in the context of exchange transfusion;

4. Major intracranial bleeding prior to the onset of severe thrombocytopenia. Neonates with major bleeding after the end of follow-up will not be excluded, but will be recorded as having had no major bleeding during the study.

• Minimum Eligible Age: 22 Weeks
• Maximum Eligible Age: 34 Weeks
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sanquin Research & Blood Bank Divisions

OTHER

Sponsor Role: collaborator

Amsterdam University Medical Center

OTHER

Sponsor Role: collaborator

Leiden University Medical Center

OTHER

Sponsor Role: lead

Responsible Party

Hilde van der Staaij, MD

MD, Coordinating Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Hilde van der Staaij, MD

Role: STUDY_DIRECTOR

Leiden University Medical Center and Sanquin Blood Supply Foundation

Johanna G van der Bom, MD/PhD/Prof

Role: PRINCIPAL_INVESTIGATOR

Leiden University Medical Center

Camila Caram-Deelder, MSc/PhD

Role: PRINCIPAL_INVESTIGATOR

Leiden University Medical Center

Enrico Lopriore, MD/PhD/Prof

Role: PRINCIPAL_INVESTIGATOR

Leiden University Medical Center

Karin Fijnvandraat, MD/PhD/Prof

Role: PRINCIPAL_INVESTIGATOR

Amsterdam University Medical Center

Suzanne F Fustolo-Gunnink, MD/PhD

Role: PRINCIPAL_INVESTIGATOR

Sanquin Blood Supply Foundation

Wes Onland, MD/PhD

Role: PRINCIPAL_INVESTIGATOR

Amsterdam University Medical Center

Nan van Geloven, MSc/PhD

Role: PRINCIPAL_INVESTIGATOR

Leiden University Medical Center

Ilaria Prosepe, MSc

Role: PRINCIPAL_INVESTIGATOR

Leiden University Medical Center

Locations

Charité - Universitätsmedizin Berlin

Berlin, Metropolregion Berlin-Brandenburg, Germany

Radboud University Medical Center, Amalia Children's hospital

Nijmegen, Gelderland, Netherlands

Maastricht University Medical Center, MosaKids

Maastricht, Limburg, Netherlands

Máxima Medical Center

Veldhoven, North Brabant, Netherlands

Amsterdam University Medical Center, Emma Children's hospital, location VUmc

Amsterdam, North Holland, Netherlands

Amsterdam University Medical Center, Emma Children's hospital, location AMC

Amsterdam, North Holland, Netherlands

Isala clinics

Zwolle, Overijssel, Netherlands

University Medical Center Groningen, Beatrix Children's hospital

Groningen, Provincie Groningen, Netherlands

Leiden University Medical Center, Willem Alexander Children's hospital

Leiden, South Holland, Netherlands

Erasmus University Medical Center, Sophia pediatric hospital

Rotterdam, South Holland, Netherlands

University Medical Center Utrecht, Wilhelmina Children's hospital

Utrecht, Utrecht, Netherlands

Karolinska University Hospital

Stockholm, Södermanland and Uppland, Sweden

Countries

Germany; Netherlands; Sweden

References

Curley A, Stanworth SJ, Willoughby K, Fustolo-Gunnink SF, Venkatesh V, Hudson C, Deary A, Hodge R, Hopkins V, Lopez Santamaria B, Mora A, Llewelyn C, D'Amore A, Khan R, Onland W, Lopriore E, Fijnvandraat K, New H, Clarke P, Watts T; PlaNeT2 MATISSE Collaborators. Randomized Trial of Platelet-Transfusion Thresholds in Neonates. N Engl J Med. 2019 Jan 17;380(3):242-251. doi: 10.1056/NEJMoa1807320. Epub 2018 Nov 2.

Reference Type: BACKGROUND

PMID: 30387697 (View on PubMed)

Davenport P, Sola-Visner M. Hemostatic Challenges in Neonates. Front Pediatr. 2021 Mar 2;9:627715. doi: 10.3389/fped.2021.627715. eCollection 2021.

Reference Type: BACKGROUND

PMID: 33738269 (View on PubMed)

Davenport PE, Wood TR, Heagerty PJ, Sola-Visner MC, Juul SE, Patel RM. Platelet Transfusion and Death or Neurodevelopmental Impairment in Children Born Extremely Preterm. JAMA Netw Open. 2024 Jan 2;7(1):e2352394. doi: 10.1001/jamanetworkopen.2023.52394.

Reference Type: BACKGROUND

PMID: 38261320 (View on PubMed)

Fustolo-Gunnink SF, Fijnvandraat K, van Klaveren D, Stanworth SJ, Curley A, Onland W, Steyerberg EW, de Kort E, d'Haens EJ, Hulzebos CV, Huisman EJ, de Boode WP, Lopriore E, van der Bom JG; PlaNeT2 and MATISSE collaborators. Preterm neonates benefit from low prophylactic platelet transfusion threshold despite varying risk of bleeding or death. Blood. 2019 Dec 26;134(26):2354-2360. doi: 10.1182/blood.2019000899.

Reference Type: BACKGROUND

PMID: 31697817 (View on PubMed)

Fustolo-Gunnink SF, Fijnvandraat K, Putter H, Ree IM, Caram-Deelder C, Andriessen P, d'Haens EJ, Hulzebos CV, Onland W, Kroon AA, Vijlbrief DC, Lopriore E, van der Bom JG. Dynamic prediction of bleeding risk in thrombocytopenic preterm neonates. Haematologica. 2019 Nov;104(11):2300-2306. doi: 10.3324/haematol.2018.208595. Epub 2019 Feb 28.

Reference Type: BACKGROUND

PMID: 30819913 (View on PubMed)

Hernan MA, Wang W, Leaf DE. Target Trial Emulation: A Framework for Causal Inference From Observational Data. JAMA. 2022 Dec 27;328(24):2446-2447. doi: 10.1001/jama.2022.21383.

Reference Type: BACKGROUND

PMID: 36508210 (View on PubMed)

Keogh RH, Van Geloven N. Prediction Under Interventions: Evaluation of Counterfactual Performance Using Longitudinal Observational Data. Epidemiology. 2024 May 1;35(3):329-339. doi: 10.1097/EDE.0000000000001713. Epub 2024 Apr 18.

Reference Type: BACKGROUND

PMID: 38630508 (View on PubMed)

van der Staaij H, Stanworth SJ, Fustolo-Gunnink SF. Prophylactic Platelet Transfusions: Why Less Is More. Clin Perinatol. 2023 Dec;50(4):775-792. doi: 10.1016/j.clp.2023.07.007. Epub 2023 Aug 31.

Reference Type: BACKGROUND

PMID: 37866847 (View on PubMed)

van Geloven N, Swanson SA, Ramspek CL, Luijken K, van Diepen M, Morris TP, Groenwold RHH, van Houwelingen HC, Putter H, le Cessie S. Prediction meets causal inference: the role of treatment in clinical prediction models. Eur J Epidemiol. 2020 Jul;35(7):619-630. doi: 10.1007/s10654-020-00636-1. Epub 2020 May 22.

Reference Type: BACKGROUND

PMID: 32445007 (View on PubMed)

Other Identifiers

22-3028

Identifier Type: -

Identifier Source: org_study_id